A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Triple Negative Breast Cancer
Related studies linked through entity extraction aliases.
Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1